Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ask Vendit Off-Topic Questions -- Ignore unavailable to you. Want to Upgrade?

To: Walkingshadow who wrote (4716)	2/8/2005 7:13:08 AM
From: Vendit™	Respond to of 8752

OSIP like’s to gap in either direction. 139.142.147.218 OSI Pharmaceuticals narrows loss (OSIP) By Russ Britt LOS ANGELES (MarketWatch) -- OSI Pharmaceuticals (OSIP) late Monday reported a net loss of $48.4 million, or $1.02 a share, for the quarter ended Dec. 31, compared with a loss of $40.1 million, or $1.03 a share for the like period a year ago. Revenue was $12.3 million vs. last year's $11.4 million. Excluding certain items, the loss was 98 cents a share, higher than the 71-cent estimate from analysts polled by Thomson First Call. The period served as a transition, as the company is shifting from a fiscal year end in September to a year ending in December. OSI shares were down in after-hours trading, to $61.80 from a close of $62.73.